Novo Nordisk's next-gen obesity drug Cagrisema
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback